Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737849 | 0.87 | CCR5 (0.51) | CCR5HTTSMN1; SMN2ALDH1A1SLC6A4 | |
| SCHEMBL21043174 | 0.83 | LMNA (0.42) | LMNANR3C1CCR5HTTPIK3CD | |
| SCHEMBL11300550 | 0.78 | HRH4 (0.42) | HRH4NR3C1CCR5HIF1ASLC6A4 | |
| SCHEMBL12930943 | 0.76 | TMEM97 (0.42) | LMNANR3C1TSHRHTTPIK3CD | |
| SCHEMBL1907350 | 0.73 | GBA1 (0.41) | LMNANR3C1CCR5TSHRHTT | |
| SCHEMBL5002861 | 0.73 | NR3C1 (0.47) | LMNANR3C1CCR5TSHRHTT | |
| SCHEMBL11299361 | 0.72 | HTR6 (0.39) | LMNAHRH4NR3C1TSHRSMN1; SMN2 | |
| SCHEMBL5657840 | 0.71 | PTGDR2 (0.42) | LMNATSHRHTTSMN1; SMN2GAA | |
| SCHEMBL20092522 | 0.71 | NR3C1 (0.51) | NR3C1TSHRHTT | |
| SCHEMBL1906296 | 0.70 | SMN1; SMN2 (0.41) | LMNANR3C1CCR5TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | LMNA 392/4885HRH4 1015/4885NR3C1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.